Coraxan Use in Patients with Cardiovascular and Pulmonary Pathology

Article Sidebar

pdf
Published: Jan 30, 2024
Keywords:
Coraxan ischemic heart disease blood pressure

Main Article Content

Rajabova N.T
PhD, Senior Lecturer, Department of Pediatrics and higher nursing, Urgench Branch of TMA, Urgench, Uzbekistan
Kilicheva T.A
Assistant of the Department of Propaedeutics of pediatric diseases, Urgench Branch of TMA, Urgench, Uzbekistan

Abstract

The article studies the efficacy of the drug Coraxan in the complex therapy of patients with coronary heart disease (CHD) and arterial hypertension (AH) in combination with chronic obstructive pulmonary disease (COPD). The use of Coraxan in the treatment of patients with combined cardiopulmonary pathology leads to a significant decrease in blood pressure (BP) and heart rate (HR), reduction of angina attacks. Coraxan increases tolerance to physical activity (PA).

Article Details

How to Cite
Rajabova N.T, & Kilicheva T.A. (2024). Coraxan Use in Patients with Cardiovascular and Pulmonary Pathology. The Peerian Journal, 26, 25–28. Retrieved from https://peerianjournal.com/index.php/tpj/article/view/744
Issue
Vol. 26 (2024): TPJ
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Ражабова, Н. Т., Шамуратова, Г. Б., & Раджапов, А. А. (2019). Исследование действия

карведилола у пациентов с дилатационной кардиомиопатией. Вопросы науки и

образования, (7 (53)), 206-210.Ташкенбаева, Э., & Ражабова, Н. (2023). ВЛИЯНИЕ ЦИТОКИНОВ В РАЗВИТИИ ИБС

У ЖЕНЩИН В ПЕРИОД МЕНОПАУЗЫ. Science and innovation in the education

system, 2(7), 28-29.

Ташкенбаева, Э., Ражабова, Н., & Матязовой, Ф. (2023). РОЛЬ ЦИТОКИНОВ В

РАЗВИТИИ ИБС У ЖЕНЩИН В ПЕРИОД МЕНОПАУЗЫ. Евразийский журнал

академических исследований, 3(6), 90-97.